

# PEER-REVIEW REPORT

Name of journal: World Journal of Cardiology

Manuscript NO: 80550

**Title:** Redefying the therapeutic strategies against Cardiorenal morbidity and mortality:

Patient phenotypes

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06277476

**Position:** Peer Reviewer

Academic degree: Doctor, FASN, FRCPA, MD, MSc, PharmD

Professional title: Chief Technician, Research Assistant, Superintendent, Technician

Reviewer's Country/Territory: China

Author's Country/Territory: Greece

Manuscript submission date: 2022-10-02

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-10-05 02:28

Reviewer performed review: 2022-10-14 01:49

Review time: 8 Days and 23 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	<ul> <li>[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing</li> <li>[ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection</li> </ul>
Conclusion	<ul> <li>[ ] Accept (High priority) [Y] Accept (General priority)</li> <li>[ ] Minor revision [ ] Major revision [ ] Rejection</li> </ul>
Re-review	[ ]Yes [Y]No



Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [ ] Yes [Y] No

#### SPECIFIC COMMENTS TO AUTHORS

The author puts forward some strategies to solve some clinical problems of CKD, and also puts forward some suggestions for development. This manuscript has good clinical value. But I think the author can use a picture to summarize these strategies and suggestions, which will make the article clearer.



### PEER-REVIEW REPORT

Name of journal: World Journal of Cardiology

Manuscript NO: 80550

**Title:** Redefying the therapeutic strategies against Cardiorenal morbidity and mortality:

Patient phenotypes

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03830490

Position: Editorial Board

Academic degree: MD

Professional title: Associate Professor

Reviewer's Country/Territory: Turkey

Author's Country/Territory: Greece

Manuscript submission date: 2022-10-02

Reviewer chosen by: Dong-Mei Wang

Reviewer accepted review: 2022-11-17 07:11

Reviewer performed review: 2022-11-17 12:40

Review time: 5 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	<ul> <li>[ ] Accept (High priority) [ ] Accept (General priority)</li> <li>[ Y] Minor revision [ ] Major revision [ ] Rejection</li> </ul>
Re-review	[Y]Yes []No



Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [ ] Yes [Y] No

#### SPECIFIC COMMENTS TO AUTHORS

Dear Author/s Greetings for you. It's a nice review about cardiorenal syndrome. In summary, the subject is well explained. It would be appropriate to briefly describe the management and treatment of anemia in cardiorenal syndrome. The new molecules HIF stabilizers may also be mentioned. Best regards



### PEER-REVIEW REPORT

Name of journal: World Journal of Cardiology

Manuscript NO: 80550

**Title:** Redefying the therapeutic strategies against Cardiorenal morbidity and mortality:

Patient phenotypes

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06186852

**Position:** Peer Reviewer

Academic degree: MBBS

Professional title: Doctor

Reviewer's Country/Territory: Sudan

Author's Country/Territory: Greece

Manuscript submission date: 2022-10-02

Reviewer chosen by: Dong-Mei Wang

Reviewer accepted review: 2022-11-19 05:50

Reviewer performed review: 2022-11-19 06:00

Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	<ul> <li>[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing</li> <li>[ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection</li> </ul>
Conclusion	<ul> <li>[ ] Accept (High priority) [ ] Accept (General priority)</li> <li>[ Y] Minor revision [ ] Major revision [ ] Rejection</li> </ul>
Re-review	[Y]Yes []No



Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [ ] Yes [Y] No

#### SPECIFIC COMMENTS TO AUTHORS

Very good manuscript and it was written well. You need t add "and" in third line after hypertension and before Dyslipidaemia.



# PEER-REVIEW REPORT

Name of journal: World Journal of Cardiology

Manuscript NO: 80550

**Title:** Redefying the therapeutic strategies against Cardiorenal morbidity and mortality:

Patient phenotypes

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05827902

**Position:** Editorial Board

Academic degree: FACC, MD

Professional title: Assistant Professor

Reviewer's Country/Territory: United States

Author's Country/Territory: Greece

Manuscript submission date: 2022-10-02

Reviewer chosen by: Dong-Mei Wang

Reviewer accepted review: 2022-11-20 00:16

Reviewer performed review: 2022-11-20 00:35

Review time: 1 Hour

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	<ul> <li>[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing</li> <li>[ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection</li> </ul>
Conclusion	<ul> <li>[ ] Accept (High priority) [ ] Accept (General priority)</li> <li>[ Y] Minor revision [ ] Major revision [ ] Rejection</li> </ul>
Re-review	[ ]Yes [Y]No



Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [ ] Yes [Y] No

#### SPECIFIC COMMENTS TO AUTHORS

The authors present their opinion on various co-morbidities associated with CKD that influence CV disease/outcomes and discuss current challenges in their management. They are correct in pointing out that although many of these co-morbidities are well known to be associated with CV disease, their management either remains inadequate or their management is not definitively associated with changes in CV outcomes. The opinion is reasonably well written.